Y Intercept Hong Kong Ltd Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Y Intercept Hong Kong Ltd acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, Holdings Channel.com reports. The firm acquired 45,817 shares of the biopharmaceutical company’s stock, valued at approximately $1,506,000.

Several other hedge funds have also bought and sold shares of the stock. State Street Corp lifted its position in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $97,199,000. Geode Capital Management LLC lifted its position in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its position in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock valued at $46,392,000 after purchasing an additional 172,180 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in Agios Pharmaceuticals by 20.5% during the third quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock valued at $38,002,000 after purchasing an additional 145,416 shares during the last quarter.

Agios Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ AGIO opened at $35.19 on Wednesday. Agios Pharmaceuticals, Inc. has a 52 week low of $27.14 and a 52 week high of $62.58. The firm’s fifty day moving average is $34.01 and its 200 day moving average is $42.92. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 3.10 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by insiders.

Analysts Set New Price Targets

AGIO has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $58.00 price target on the stock. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.